Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
[Is there progress in the chemotherapy of small cell lung cancer?]
Calderoni A, Cerny T, Betticher D. [Is there progress in the chemotherapy of small cell lung cancer?]. Schweizerische medizinische Wochenschrift 1999; 129:1313-20.
Sep 18, 1999[Is there progress in the chemotherapy of small cell lung cancer?]
Sep 18, 1999Schweizerische medizinische Wochenschrift 1999; 129:1313-20
Calderoni A, Cerny Thomas, Betticher D C
[Yellow nail syndrome]
Köberle D, Henz S, Flury D, Mayer R. [Yellow nail syndrome]. Schweizerische medizinische Wochenschrift 1999; 129:1342.
Sep 18, 1999[Yellow nail syndrome]
Sep 18, 1999Schweizerische medizinische Wochenschrift 1999; 129:1342
Köberle Dieter, Henz Samuel, Flury D, Mayer R
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK)
Cerny T, Brunner J, Sessa C, Honegger P, Schmitz S, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:1087-94.
Sep 1, 1999Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK)
Sep 1, 1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:1087-94
Cerny Thomas, Brunner J, Sessa C, Honegger P, Schmitz S F, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A V
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9.
Jun 1, 1999Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Jun 1, 1999Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S F, Thürlimann Beat, Hürny C
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1999; 35:913-20.
Jun 1, 1999Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Jun 1, 1999European journal of cancer (Oxford, England : 1990) 1999; 35:913-20
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Thürlimann Beat, Schmitz S F, Castiglione-Gertsch M, Hürny C
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess D, Thürlimann B, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45.
May 1, 1999Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
May 1, 1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Sabbioni M, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann B, Bernhard J, Bacchi M, Siegrist H, Hürny C, Castiglione M, Senn H. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53.
May 1, 1999Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
May 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53
Sabbioni M E, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann Beat, Bernhard J, Bacchi M, Siegrist H P, Hürny C, Castiglione M, Senn H J
Relapse and subarachnoid dissemination of a pineal germinoma 14 years after radiation therapy
Von Rohr E, Gönner F, Schroth G, Cerny T. Relapse and subarachnoid dissemination of a pineal germinoma 14 years after radiation therapy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 1999; 6:247-9.
May 1, 1999Relapse and subarachnoid dissemination of a pineal germinoma 14 years after radiation therapy
May 1, 1999Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 1999; 6:247-9
Von Rohr E, Gönner F, Schroth G, Cerny Thomas
Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood
Reinhart W, Baerlocher G, Cerny T, Owen G, Meiselman H, Beer J. Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. European journal of haematology 1999; 62:223-30.
Apr 1, 1999Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood
Apr 1, 1999European journal of haematology 1999; 62:223-30
Reinhart W H, Baerlocher G M, Cerny Thomas, Owen G R, Meiselman H J, Beer J H
T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease
Bättig B, Mueller-Garamvoelgyi E, Cogliatti S, Schmid U, Kappeler A, Cerny T, Laissue J, Fey M. T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease. Leukemia & lymphoma 1999; 33:393-8.
Apr 1, 1999T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease
Apr 1, 1999Leukemia & lymphoma 1999; 33:393-8
Bättig B, Mueller-Garamvoelgyi E, Cogliatti S B, Schmid U, Kappeler A, Cerny Thomas, Laissue J A, Fey M F
[Quality of life of patients with metastatic breast or intestinal cancer, treated with anthroposophic medicine or with mainstream medicine, the latter with or without psycho-oncologic or supplementary anthroposophic therapy]
Cerny T, Heusser P. [Quality of life of patients with metastatic breast or intestinal cancer, treated with anthroposophic medicine or with mainstream medicine, the latter with or without psycho-oncologic or supplementary anthroposophic therapy]. Forschende Komplementärmedizin 1999; 6 Suppl 1:35-7.
Feb 1, 1999[Quality of life of patients with metastatic breast or intestinal cancer, treated with anthroposophic medicine or with mainstream medicine, the latter with or without psycho-oncologic or supplementary anthroposophic therapy]
Feb 1, 1999Forschende Komplementärmedizin 1999; 6 Suppl 1:35-7
Cerny Thomas, Heusser P
Frühe Prägung - Frühe Störung - Ressourcen
Renz M, Riedel L. Frühe Prägung - Frühe Störung - Ressourcen. In: Wahnsinn und Normalität. Riehen: Perspectiva, 1999. pp. 243-262.
Jan 1, 1999Frühe Prägung - Frühe Störung - Ressourcen
Jan 1, 1999Perspectiva
Renz Monika, Riedel L
Aller Anfang ist Übergang
Renz M, Herzka H, Reukauf W, Wintsch H. Aller Anfang ist Übergang. In: Dialogik in Psychologie und Medizin. Basel: Schwabe, 1999. pp. 32-40.
Jan 1, 1999Aller Anfang ist Übergang
Jan 1, 1999Schwabe
Renz Monika, Herzka Heinz Stefan, Reukauf Wolf, Wintsch Hanna
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Köberle D, Bacchus L, Thürlimann B, Senn H. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7.
Jan 1, 1999Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Jan 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7
Köberle Dieter, Bacchus L, Thürlimann Beat, Senn H J
Hormonal treatment of breast cancer: new developments
Thürlimann B. Hormonal treatment of breast cancer: new developments. Oncology 1998; 55:501-7.
Nov 1, 1998Hormonal treatment of breast cancer: new developments
Nov 1, 1998Oncology 1998; 55:501-7
Thürlimann Beat
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Engler H, Köberle D, Thürlimann B, Senn H, Riesen W. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85.
Nov 1, 1998Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Nov 1, 1998Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85
Engler H, Köberle Dieter, Thürlimann Beat, Senn H J, Riesen W F
Lymphocytic colitis: clinical presentation and long term course
Mullhaupt B, Gueller U, Anabitarte M, Güller R, Fried M. Lymphocytic colitis: clinical presentation and long term course. Gut 1998; 43:629-33.
Nov 1, 1998Lymphocytic colitis: clinical presentation and long term course
Nov 1, 1998Gut 1998; 43:629-33
Mullhaupt B, Gueller Ulrich, Anabitarte M, Güller R, Fried M
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
Stupp R, Giroux B, Schläpfer J, Sarkany M, Bastian G, Sessa C, Cerny T, Gerard B, Pagani O, Bauer J, Leyvraz S. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1233-42.
Nov 1, 1998Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
Nov 1, 1998Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1233-42
Stupp R, Giroux B, Schläpfer J, Sarkany M, Bastian G, Sessa C, Cerny Thomas, Gerard B, Pagani O, Bauer J, Leyvraz S
Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group
Colleoni M, Thürlimann B, Gelber R, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700.
Oct 1, 1998Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group
Oct 1, 1998European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700
Colleoni M, Thürlimann Beat, Gelber R D, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C M
The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer
Van Wegberg B, Castiglione M, Hürny C, Bernhard J, Von Rohr E, Schaad R, Helwig S, Heusser P, Bacchi M, Cerny T. The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1091-6.
Oct 1, 1998The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer
Oct 1, 1998Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1091-6
Van Wegberg B, Castiglione M, Hürny C, Bernhard J, Von Rohr E, Schaad R, Helwig S, Heusser P, Bacchi M, Cerny Thomas